BAX Baxter International (BAX) Insider Trading, Ownership & Congress Trades
Medical Devices · Surgical & medical instruments & apparatus · CIK 0000010456
Congress · 1
Insider buyers, 180 days
0
Funds added, last quarter
0
13F, latest reported quarter
What the filings say about BAX
Congress, 1 year
1 bought · 1 sold
Latest: sale, 2025-10-31
Baxter International insider trades (Form 4)
Form 4 buys and sells (codes P and S). Grants, option exercises
and conversions excluded.
No insider purchases or sales are on record for BAXTER INTERNATIONAL INC in the period covered. Source: SEC Form 4 filings, as of 2026-10-28.
Insider
Filed
Shares
Value
Since filing
Context
- 3 earlier Form 4 trades (code P or S) here by this insider (3 sales), the last on Jan 17, 2023.
- The trade is 45.3% of the 142,290 shares held after it.
- No other insider sold within 30 days.
Insider activity: EVP, Chief HR Officer Mason Jeanne K sold about $2.6M of BAX on Mar 1, 2024, the largest insider sale at the company since 2023.Context
- 2 earlier Form 4 trades (code P or S) here by this insider (2 sales), the last on Apr 5, 2022.
- The trade is 10.7% of the 36,835 shares held after it.
- 1 other insider sold within 30 days.
Insider activity: Director STROUCKEN ALBERT P L sold about $147.5K of BAX on Mar 20, 2023; 1 other insider sold within 30 days.Context
- First Form 4 purchase or sale (code P or S) here by this insider on our record.
- The trade is 22.8% of the 16,725 shares held after it.
- 1 other insider sold within 30 days.
Insider activity: SVP, Chief Quality Officer Kunzler Jacqueline sold about $154.4K of BAX on Feb 21, 2023; 1 other insider sold within 30 days.Context
- 2 earlier Form 4 trades (code P or S) here by this insider (2 sales), the last on Feb 14, 2022.
- The trade is 47.1% of the 126,231 shares held after it.
- No other insider sold within 30 days.
Insider activity: SVP, Human Resources Mason Jeanne K sold about $2.7M of BAX on Jan 17, 2023.Context
- First Form 4 purchase or sale (code P or S) here by this insider on our record.
- The trade is 3.6% of the 34,127 shares held after it.
- 2 other insiders sold within 30 days.
Insider activity: Director STROUCKEN ALBERT P L sold about $93.1K of BAX on Apr 5, 2022; 2 other insiders sold within 30 days.19 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
Seven facts, ranked against the sector ·
Rank is not a forecast
Insiders
no insider buys or sells on file
Congress
1 member bought in the last year
the lowest in Medical Devices
Funds
under five funds report holding it
Revenue
+5.7% year over year
below 63% of Medical Devices
Margin
-8.5% net margin
more than 58% of Medical Devices
Buybacks
no share repurchases reported
Short interest
4.7% of the float short (float per yahoo 2026-10-26) · 3.0 days to cover · settled 2026-09-30
more than 62% of Medical Devices
What changed in the last 30 days
Nothing new filed in the last 30 days
Watch BAX
A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.
The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
+8.6%12M
Indexed to 100, dividend-adjusted, not a price chart.
When a name files heavily, the largest trades are drawn first.
Who owns BAX: institutional holders (13F)
13F holdings, latest reported quarter
SEC 13F
No reported 13F holders
No fund above the reporting threshold listed this stock last quarter. That is a fact, not missing data.
Congress trades in BAX
STOCK Act disclosures, US House only, filed up to 45 days after the trade
Sold 2025-10-31 · disclosed 21 days later
$1,001 - $15,000
Bought 2025-10-30 · disclosed 22 days later
$1,001 - $15,000
Sold 2025-10-30 · disclosed 22 days later
$1,001 - $15,000
Bought 2025-09-25 · disclosed 27 days later
$1,001 - $15,000
Sold 2025-08-04 · disclosed 39 days later
$1,001 - $15,000
Activist and 5% holders (13D/13G)
No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.
BAX planned insider sales (Form 144)
No planned-sale notices
No insider has filed to sell. Watch this after a run-up.
Government contracts
Award ceilings over the contract's life, subsidiaries included.
Not annual revenue (USASpending.gov).
Department Of Health And Human Services
SODIUM CHLORIDE (NACL), 0.9% FOR INJECTION, 100ML SOLUTION FLEXI-BAG · 2025-09-01
$18.8M
Federal awards ≥ $25M in the last 90 days, matched via the SAM.gov parent registry
Executive pay vs shareholder return · Mr.Almeida
CEO pay, headline and as actually paid, against the company's
return and its chosen peers' (DEF 14A).
FY
CEO total
Actually paid
Other execs, avg
TSR
Peer TSR
2024
$18.1M
$9.2M
$6.5M
-60%
+29%
2023
$13.8M
$10.4M
$5.2M
-49%
+26%
2022
$13.6M
-$9.1M
$6.7M
-34%
+24%
2021
$15.6M
$19.6M
$4.9M
+8%
+26%
2020
$15.9M
$4.1M
$3.9M
-3%
+13%
Tagged by the company under SEC Item 402(v). Returns are
cumulative from the start of the disclosure period. Green where the company beat its own peer group.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
The complete filing record, in one place.
The record shows 1 House member(s) bought in 12 months, disclosed weeks after the trade. Each figure is a federal filing, dated the day it went public.
BAX financials
Revenue growth
+5.7%
XBRL, annual
Net margin
-8.5%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$11.5B
four quarters, 2025-07-01 to 2026-06-30
Revenue, TTM BAX
| FY Dec 2025 | $11.2B |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | $12.8B |
| Jun 2026 | $3.0B |
| Mar 2026 | $2.7B |
| Dec 2025 | $3.0B |
| Sep 2025 | $2.8B |
| Jun 2025 | $2.8B |
| Mar 2025 | $2.6B |
| Dec 2024 | $2.8B |
| Sep 2024 | $2.7B |
At each fiscal year end
Single quarter
Net margin, TTM
-9.3%
net income over revenue, 2025-07-01 to 2026-06-30
Net margin, TTM BAX
| FY Dec 2025 | -8.5% |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | +10.0% |
| Jun 2026 | +4.3% |
| Mar 2026 | -0.6% |
| Dec 2025 | -37.9% |
| Sep 2025 | -1.6% |
| Jun 2025 | +3.2% |
| Mar 2025 | +4.8% |
| Dec 2024 | -18.6% |
| Sep 2024 | +5.2% |
At each fiscal year end
Single quarter
Free cash flow, TTM
$815.0M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Free cash flow, TTM BAX
| FY Dec 2025 | $332.0M |
| FY Dec 2024 | $573.0M |
| FY Dec 2023 | $1.3B |
| FY Dec 2022 | $834.0M |
| FY Dec 2021 | $1.5B |
| Jun 2026 | $169.0M |
| Mar 2026 | $76.0M |
| Dec 2025 | $444.0M |
| Sep 2025 | $126.0M |
| Jun 2025 | $77.0M |
| Mar 2025 | -$315.0M |
| Dec 2024 | $356.0M |
| Sep 2024 | $119.0M |
At each fiscal year end
Single quarter
Debt to equity
1.52x
long-term 2025-12-31 (6 months older than the period end) plus current 2026-06-30; equity 2026-06-30
Debt to equity BAX
| FY Dec 2025 | 1.54x |
| FY Dec 2024 | 2.20x |
| FY Dec 2023 | 1.65x |
| FY Dec 2022 | 2.91x |
| FY Dec 2021 | 1.99x |
| Jun 2026 | 1.52x |
| Mar 2026 | 1.56x |
| Dec 2025 | 1.54x |
| Sep 2025 | 1.82x |
| Jun 2025 | 1.80x |
| Mar 2025 | 1.86x |
| Dec 2024 | 2.20x |
| Sep 2024 | 1.33x |
At each fiscal year end
Trailing four quarters at each quarter end
Cash flow to debt
0.14x
TTM operating cash flow over long-term 2025-12-31 (6 months older than the period end) plus current 2026-06-30
Cash flow to debt BAX
| FY Dec 2025 | 0.09x |
| FY Dec 2024 | 0.07x |
| FY Dec 2023 | 0.12x |
| FY Dec 2022 | 0.07x |
| FY Dec 2021 | 0.12x |
| Jun 2026 | 0.14x |
| Mar 2026 | 0.13x |
| Dec 2025 | 0.09x |
| Sep 2025 | 0.06x |
| Jun 2025 | 0.06x |
| Mar 2025 | 0.05x |
| Dec 2024 | 0.07x |
| Sep 2024 | 0.10x |
At each fiscal year end
Trailing four quarters at each quarter end
Return on equity
-15.7%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on equity BAX
| FY Dec 2025 | -14.6% |
| FY Dec 2024 | -8.4% |
| FY Dec 2023 | +37.3% |
| FY Dec 2022 | -32.6% |
| FY Dec 2021 | +14.5% |
| Jun 2026 | -15.7% |
| Mar 2026 | -16.7% |
| Dec 2025 | -14.6% |
| Sep 2025 | -4.5% |
| Jun 2025 | -2.1% |
| Mar 2025 | -7.3% |
| Dec 2024 | -8.4% |
| Sep 2024 | +1.4% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on assets
-5.2%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets BAX
| FY Dec 2025 | -4.2% |
| FY Dec 2024 | -2.4% |
| FY Dec 2023 | +9.4% |
| FY Dec 2022 | -7.9% |
| FY Dec 2021 | +4.8% |
| Jun 2026 | -5.2% |
| Mar 2026 | -5.3% |
| Dec 2025 | -4.2% |
| Sep 2025 | -1.4% |
| Jun 2025 | -0.7% |
| Mar 2025 | -2.3% |
| Dec 2024 | -2.4% |
| Sep 2024 | +0.4% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on invested capital
n/a
pre-tax loss, no effective tax rate to apply
Return on invested capital BAX
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | +5.3% |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on capital employed
-1.6%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
Return on capital employed BAX
| FY Dec 2025 | -1.7% |
| FY Dec 2024 | +0.1% |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | +5.9% |
| Jun 2026 | -1.6% |
| Mar 2026 | -1.8% |
| Dec 2025 | -1.7% |
| Sep 2025 | -0.1% |
| Jun 2025 | -0.2% |
| Mar 2025 | -0.2% |
| Dec 2024 | +0.1% |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
P/E, trailing BAX
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | 7.41x |
| FY Dec 2022 | n/a |
| FY Dec 2021 | 33.93x |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | 180.81x |
At each fiscal year end
Trailing four quarters at each quarter end
Enterprise value
$20.2B
market value at close 2026-10-27 on 2026-07-23 shares, plus long-term 2025-12-31 (6 months older than the period end) plus current 2026-06-30, minus cash 2026-06-30
Enterprise value BAX
| FY Dec 2025 | $17.3B |
| FY Dec 2024 | $28.4B |
| FY Dec 2023 | $30.4B |
| FY Dec 2022 | $41.1B |
| FY Dec 2021 | $58.1B |
| Jun 2026 | $18.3B |
| Mar 2026 | $16.1B |
| Dec 2025 | $17.3B |
| Sep 2025 | $23.2B |
| Jun 2025 | $27.0B |
| Mar 2025 | $28.4B |
| Dec 2024 | $28.4B |
| Sep 2024 | $28.4B |
At each fiscal year end
Trailing four quarters at each quarter end
FCF yield
+6.3%
TTM free cash flow over market value at close 2026-10-27
FCF yield BAX
| FY Dec 2025 | +3.4% |
| FY Dec 2024 | +3.8% |
| FY Dec 2023 | +6.6% |
| FY Dec 2022 | +3.2% |
| FY Dec 2021 | +3.6% |
| Jun 2026 | +7.4% |
| Mar 2026 | +8.4% |
| Dec 2025 | +3.4% |
| Sep 2025 | +2.1% |
| Jun 2025 | +1.5% |
| Mar 2025 | +1.2% |
| Dec 2024 | +3.8% |
| Sep 2024 | +4.2% |
At each fiscal year end
Trailing four quarters at each quarter end
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
PEG, trailing BAX
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | 1.86x |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Price as of 2026-10-27. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
| 2025-12 | 2024-12 | 2023-12 | 2022-12 | |
|---|---|---|---|---|
| Revenue | $11.2B | $10.6B | $14.8B | $15.1B |
| Gross profit | $3.4B | $4.0B | $4.2B | $3.5B |
| Operating income | -$308.0M | $14.0M | $707.0M | -$2.8B |
| Net income | -$957.0M | -$649.0M | $2.7B | -$2.4B |
| EPS (diluted) | -1.87 | -1.27 | 5.23 | -4.83 |
| Operating cash flow | $845.0M | $1.0B | $1.7B | $1.2B |
| Cash | $2.0B | $1.8B | $3.1B | $1.6B |
| Long-term debt | $9.4B | $13.2B | $13.9B | $16.7B |
| Buybacks | n/a | $0 | $0 | $32.0M |
| Dividends paid | $348.0M | $590.0M | $586.0M | $573.0M |
SEC XBRL, fiscal years, as known on 2026-10-28
BAX Stock Sonar score 5/7 axes
Find similar shapesCompareBAX ranks highest on profitability (60th percentile) and financial health (39th), and lowest on risk and compliance (19th), among Medical Devices peers.
5 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored
BAX filings, in plain words
Have members of Congress traded BAX?
Yes. In the year to 2026-10-28, 1 House member disclosed buying BAX and 1 House member disclosed selling it; the latest on record is a sale by Lisa McClain dated 2025-10-31.
Read the full summary
In the year to 2026-10-28, 1 member of Congress disclosed buying BAX and 1 member disclosed selling it; the latest on record is a sale by Lisa McClain dated 2025-10-31. Each figure is counted from SEC and House filings as of 2026-10-28, dated the day the filing was made public.
Explore insider trading and ownership data
Every company we track, ranked by each kind of filing
